Vaughan David Investments Inc. IL trimmed its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 169,004 shares of the medical research company’s stock after selling 1,641 shares during the quarter. Amgen comprises 1.5% of Vaughan David Investments Inc. IL’s investment portfolio, making the stock its 12th biggest holding. Vaughan David Investments Inc. IL’s holdings in Amgen were worth $31,511,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Financial Advisory Service Inc. raised its stake in shares of Amgen by 0.3% during the 2nd quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after buying an additional 5 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after buying an additional 5 shares in the last quarter. Ballentine Partners LLC raised its stake in shares of Amgen by 0.3% during the 2nd quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after buying an additional 9 shares in the last quarter. Hudock Capital Group LLC raised its stake in shares of Amgen by 0.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after buying an additional 10 shares in the last quarter. Finally, Arvest Bank Trust Division raised its stake in shares of Amgen by 0.9% during the 2nd quarter. Arvest Bank Trust Division now owns 1,508 shares of the medical research company’s stock worth $260,000 after buying an additional 13 shares in the last quarter. 78.48% of the stock is owned by institutional investors.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,575 shares of company stock worth $1,508,836. 0.19% of the stock is owned by insiders.
Shares of Amgen, Inc. (NASDAQ AMGN) opened at $189.28 on Monday. The company has a market capitalization of $137,400.00, a price-to-earnings ratio of 17.10, a price-to-earnings-growth ratio of 2.78 and a beta of 1.36. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. Amgen, Inc. has a fifty-two week low of $150.38 and a fifty-two week high of $191.10.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. Amgen’s quarterly revenue was down .7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.02 EPS. equities research analysts forecast that Amgen, Inc. will post 12.69 earnings per share for the current year.
Amgen announced that its board has initiated a stock repurchase program on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 2.79%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio is 41.55%.
A number of equities analysts have recently issued reports on AMGN shares. BMO Capital Markets reissued a “hold” rating and set a $199.00 target price on shares of Amgen in a research note on Monday, September 25th. Jefferies Group reissued a “buy” rating and set a $200.00 target price on shares of Amgen in a research note on Monday, September 25th. Mizuho reissued a “buy” rating and set a $198.00 target price (up from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Credit Suisse Group reissued a “neutral” rating and set a $186.00 target price (up from $177.00) on shares of Amgen in a research note on Friday, September 29th. Finally, Bank of America increased their target price on Amgen to $210.00 and gave the stock a “buy” rating in a research note on Thursday, October 5th. Fifteen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Amgen currently has an average rating of “Hold” and a consensus target price of $190.15.
COPYRIGHT VIOLATION WARNING: “Vaughan David Investments Inc. IL Sells 1,641 Shares of Amgen, Inc. (AMGN)” was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.truebluetribune.com/2018/01/22/vaughan-david-investments-inc-il-sells-1641-shares-of-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.